EP3209676A4 - Cancer and skin lesion treatment - Google Patents

Cancer and skin lesion treatment Download PDF

Info

Publication number
EP3209676A4
EP3209676A4 EP15853497.4A EP15853497A EP3209676A4 EP 3209676 A4 EP3209676 A4 EP 3209676A4 EP 15853497 A EP15853497 A EP 15853497A EP 3209676 A4 EP3209676 A4 EP 3209676A4
Authority
EP
European Patent Office
Prior art keywords
cancer
skin lesion
lesion treatment
treatment
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP15853497.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3209676A1 (en
Inventor
Tim Ioannides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hpvvax LLC
Original Assignee
Hpvvax LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax LLC filed Critical Hpvvax LLC
Publication of EP3209676A1 publication Critical patent/EP3209676A1/en
Publication of EP3209676A4 publication Critical patent/EP3209676A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP15853497.4A 2014-10-24 2015-10-23 Cancer and skin lesion treatment Ceased EP3209676A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068332P 2014-10-24 2014-10-24
PCT/US2015/057150 WO2016065281A1 (en) 2014-10-24 2015-10-23 Cancer and skin lesion treatment

Publications (2)

Publication Number Publication Date
EP3209676A1 EP3209676A1 (en) 2017-08-30
EP3209676A4 true EP3209676A4 (en) 2018-03-28

Family

ID=55761638

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15853497.4A Ceased EP3209676A4 (en) 2014-10-24 2015-10-23 Cancer and skin lesion treatment

Country Status (15)

Country Link
US (1) US10238729B2 (enExample)
EP (1) EP3209676A4 (enExample)
JP (1) JP6663438B2 (enExample)
KR (1) KR102285401B1 (enExample)
CN (1) CN107001430A (enExample)
AU (1) AU2015335652B2 (enExample)
BR (1) BR112017008280A2 (enExample)
CA (1) CA2965498A1 (enExample)
CL (1) CL2017001008A1 (enExample)
IL (1) IL251825B2 (enExample)
MX (1) MX395186B (enExample)
MY (1) MY195018A (enExample)
PH (1) PH12017500754A1 (enExample)
SG (1) SG11201703262UA (enExample)
WO (1) WO2016065281A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO2018009205A2 (es) * 2016-02-27 2018-09-20 Hpvvax Llc Método y composición para tratamiento del cáncer o una lesión de la piel utilizando una vacuna

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354662T1 (de) * 2001-03-23 2007-03-15 Deutsches Krebsforsch Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
ATE503492T1 (de) 2002-12-20 2011-04-15 Glaxosmithkline Biolog Sa Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
WO2005123125A1 (en) * 2004-06-16 2005-12-29 Glaxosmithkline Biologicals S.A. Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
US8399610B2 (en) 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
EP2129394B1 (en) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
CN101530612A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 16型重组人乳头瘤病毒疫苗
CN101530614A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 五价重组人乳头瘤病毒疫苗
US20110110979A1 (en) 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
US9149503B2 (en) * 2009-04-10 2015-10-06 The Johns Hopkins University Papillomavirus-like particles (VLP) as broad spectrum human papillomavirus (HPV) vaccines
EP3427755B1 (en) * 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
PL2444103T3 (pl) 2009-06-19 2018-05-30 Eyegene Inc. Szczepionka przeciwko rakowi szyjki macicy
AU2010264695A1 (en) * 2009-06-25 2012-01-19 Glaxosmithkline Biologicals S.A. Novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
US8809562B2 (en) * 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
WO2013139744A1 (en) * 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
WO2013149017A1 (en) * 2012-03-28 2013-10-03 Kansas State University Research Foundation Vaccine adjuvant
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2014331654A1 (en) 2013-10-13 2016-05-12 The Board Of Trustees Of The University Of Arkansas Human papilloma virus therapeutic vaccine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Complete resolution of chronic multiple verruca vulgaris treated with quadrivalent human papilloma virus (HPV) vaccine ED - Lim Henry W", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY, INC, US, vol. 64, no. 2, 1 February 2011 (2011-02-01), pages AB110, XP027591671, ISSN: 0190-9622, [retrieved on 20110112], DOI: 10.1016/J.JAAD.2010.09.479 *
ANNA J. NICHOLS ET AL: "Association of Human Papillomavirus Vaccine With the Development of Keratinocyte Carcinomas", JAMA DERMATOLOGY, vol. 153, no. 6, 1 June 2017 (2017-06-01), US, pages 571, XP055449608, ISSN: 2168-6068, DOI: 10.1001/jamadermatol.2016.5703 *
ANNA J. NICHOLS ET AL: "Combined Systemic and Intratumoral Administration of Human Papillomavirus Vaccine to Treat Multiple Cutaneous Basaloid Squamous Cell Carcinomas", JAMA DERMATOLOGY, vol. 154, no. 8, 1 August 2018 (2018-08-01), US, pages 927, XP055537673, ISSN: 2168-6068, DOI: 10.1001/jamadermatol.2018.1748 *
DANIELA LEDIC DRVAR ET AL: "Human papillomavirus status in extragenital nonmelanoma skin cancers", CLINICS IN DERMATOLOGY., vol. 32, no. 2, 1 March 2014 (2014-03-01), US, pages 248 - 252, XP055449921, ISSN: 0738-081X, DOI: 10.1016/j.clindermatol.2013.08.009 *
MEGAN N. LANDIS ET AL: "Recalcitrant plantar warts treated with recombinant quadrivalent human papillomavirus vaccine", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY., vol. 67, no. 2, 1 August 2012 (2012-08-01), US, pages e73 - e74, XP055449832, ISSN: 0190-9622, DOI: 10.1016/j.jaad.2011.08.022 *
SABRINA E VINZÓN ET AL: "HPV vaccination for prevention of skin cancer", HUMAN VACCINES AND IMMUNOTHERAPEUTICS, vol. 11, no. 2, 1 February 2015 (2015-02-01), US, pages 353 - 357, XP055449964, ISSN: 2164-5515, DOI: 10.4161/21645515.2014.983858 *
SABRINA E VINZÓN ET AL: "Protective vaccination against papillomavirus-induced skin tumors under immunocompetent and immunosuppressive conditions: a preclinical study using a natural outbred animal model", PLOS PATHOGENS, 1 February 2014 (2014-02-01), United States, pages e1003924, XP055449968, Retrieved from the Internet <URL:http://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1003924&type=printable> DOI: 10.1371/journal.ppat.1003924 *
See also references of WO2016065281A1 *
TZU-YU LIU ET AL: "Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 12, no. 14, 1 August 2012 (2012-08-01), HILVERSUM; NL, pages 1581 - 1592, XP055357170, ISSN: 1568-0266, DOI: 10.2174/156802612802652402 *

Also Published As

Publication number Publication date
MY195018A (en) 2023-01-03
WO2016065281A1 (en) 2016-04-28
US20160114023A1 (en) 2016-04-28
JP6663438B2 (ja) 2020-03-11
BR112017008280A2 (pt) 2018-01-02
CL2017001008A1 (es) 2017-11-24
EP3209676A1 (en) 2017-08-30
SG11201703262UA (en) 2017-05-30
KR20170072279A (ko) 2017-06-26
KR102285401B1 (ko) 2021-08-02
US10238729B2 (en) 2019-03-26
CN107001430A (zh) 2017-08-01
MX2017005418A (es) 2017-11-30
CA2965498A1 (en) 2016-04-28
IL251825B1 (en) 2023-05-01
AU2015335652A1 (en) 2017-05-25
JP2017531699A (ja) 2017-10-26
IL251825B2 (en) 2023-09-01
AU2015335652B2 (en) 2020-07-02
IL251825A0 (en) 2017-06-29
MX395186B (es) 2025-03-21
PH12017500754A1 (en) 2017-10-30

Similar Documents

Publication Publication Date Title
IL255372A0 (en) Therapeutic and diagnostic methods for cancer
IL255312A0 (en) Therapeutic and diagnostic methods for cancer
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
EP3160566A4 (en) Tissue sampling and cancer treatment methods and apparatus
EP3174538A4 (en) Methods and therapeutic combinations for treating tumors
EP3099274A4 (en) Vascular and bodily duct treatment devices and methods
IL248455B (en) igf-1r antibody-drug conjugate and its use for cancer treatment
EP3180000A4 (en) Cancer diagnosis and therapy
EP3148526A4 (en) Use of eribulin in the treatment of cancer
EP3169321A4 (en) Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
EP3191103A4 (en) Compositions and methods for treatment of pre-cancerous skin lesions
PT3151814T (pt) Tratamento de uma lesão da pele
EP3148556A4 (en) Skin treatment formulations
EP3151821A4 (en) Marmelin analogs and methods of use in cancer treatment
GB201409363D0 (en) Skin cancer treatment
EP3137129A4 (en) Systems and methods for tissue treatment
EP3154637A4 (en) Treatment of virus-based diseases of the skin
ZA201807325B (en) Treatment of skin lesions
EP3119307A4 (en) Skin treatment devices and methods
IL251825B1 (en) Treatment of cancer and skin damage
HK40021842A (en) Skin treatment methods
HK40018432A (en) Usl-311 for use in the treatment of cancer
EP3171879A4 (en) Preventing and treating inflammatory skin diseases
GB201703768D0 (en) Skin treatment methods
GB201703734D0 (en) Skin treatment methods

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180222

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/025 20060101AFI20180217BHEP

Ipc: A61K 39/00 20060101ALI20180217BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190107

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20220111